intermittent fasting on tirzepatide Combination of prolonged water and GLP-1 for refractory morbid obesity: Case report Weight regain after the withdrawal

doi: 10.2174/1573399816666200705210006

Reconstitution and handling Retatrutide is supplied as a lyophilised vial and should be handled using standard peptide reconstitution procedures appropriate to the research setting

PMCID: PMC3215082

The phase 2 NEJM-published data showing up to 20% weight loss at 52 weeks with monthly injections and GI side effects concentrated at the first dose are

Cardiovascular factors: Obesity is associated with increased cardiovascular risk

If the heart muscle is depleted of CoQ10 and L-carnitine, it cannot efficiently burn fatty acids to meet this heightened demand, exacerbating symptoms of severe tachycardia, chest pain, shortness of breath, and profound, whole-body exhaustion